sapropterin dihydrochloride
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonuria
Conditions
Phenylketonuria
Trial Timeline
Feb 1, 2009 → Sep 14, 2018
NCT ID
NCT00838435About sapropterin dihydrochloride
sapropterin dihydrochloride is a phase 3 stage product being developed by BioMarin Pharmaceutical for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT00838435. Target conditions include Phenylketonuria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00484991 | Pre-clinical | Completed |
| NCT01274026 | Pre-clinical | Completed |
| NCT01141595 | Pre-clinical | Completed |
| NCT00838435 | Phase 3 | Completed |
| NCT00445978 | Phase 2 | Completed |
| NCT00403494 | Phase 2 | Completed |
| NCT00332189 | Phase 3 | Completed |
| NCT00225615 | Phase 3 | Completed |
| NCT00104260 | Phase 2 | Completed |
Competing Products
20 competing products in Phenylketonuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 69 |
| SYNB1618 + Placebo | Synlogic | Phase 1/2 | 33 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 44 |
| Kuvan® | Merck | Phase 3 | 77 |
| Kuvan® | Merck | Approved | 85 |
| SAR444836 | Sanofi | Phase 1/2 | 40 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 20 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 49 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 20 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 49 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 38 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Sapropterin dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 74 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 82 |
| sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo | BioMarin Pharmaceutical | Phase 1 | 30 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 20 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |